Dynavax to Present Data on Phase 2/3 Clinical Trial of TOLAMBA at AAAAI 2006
BERKELEY, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced that safety and efficacy data from the company's Phase 2/3 clinical trial of TOLAMBA™, its ISS-based ragweed allergy immunotherapeutic, will be presented in an oral abstract session at the Annual Meeting of the American Association of Allergy, Asthma and Immunology (AAAAI), Saturday, March 4, 2006, in Miami, Florida.
The data will be presented by the principal investigator for the trial, Dr. William W. Busse, MD, Professor of Medicine, University of Wisconsin-Madison, Clinical Science Center and a past president of AAAAI.
The presentation (abstract number 345) is entitled, "Phase 2/3 Study of the Novel Vaccine Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate AIC in Ragweed Allergic Adults." The oral abstract session (number 2607) is entitled, "Allergy Diagnostics and Treatment Options" and is scheduled to take place in room C-123, located on the first level of the Miami Beach Convention Center, from 2:00-3:15 pm Eastern. Dr. Busse's presentation is scheduled for 2:20-2:30 pm Eastern.
Attendees of AAAAI are invited to visit with Dynavax management at the Dynavax Technologies booth in the exhibit hall of the Miami Beach Convention Center throughout the meeting. The booth number is 744.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic that has completed a Phase 2/3 clinical trial and is currently in a supportive clinical trial in ragweed-allergic children; HEPLISAV, a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacologic activity in a Phase 2a clinical trial.
SOURCE Dynavax Technologies Corporation
02/15/2006
CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications of
Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com
Web site: http://www.dynavax.com
(DVAX)
02/15/2006 06:00 EST http://www.prnewswire.com